Help Us Shape the Future of Treatment for Cats with Anemia due to CKD

PLEASE SHARE THIS EXCITING OPPORTUNITY WITH OTHERS IN YOUR AREA.

We are actively seeking to enroll cats that have been verified to be in IRIS Stage II-IV CKD and have a PCV ≤ 25 to participate in our latest FDA regulated study. We could use your help finding eligible cats in the NYC area. This is an opportunity to offer feline patients with CKD-related anemia a new option and to be part of a team that advances a whole new area of therapy in veterinary medicine.

CKD cats with anemia are hard to identify before they present in uremic crisis. Additionally, there are currently no FDA approved products proven safe and effective in cats. As such, dedicated, caring owners are often desperate for solutions when an anemic case is identified early on.

We are delighted to extend the reach of our ongoing trial by expanding enrollment in your area. With your help, we can find appropriate patients to participate in this cutting edge gene therapy study to help improve quality of life for older companion animal cats. By sharing this information, you become a valuable part of the team striving to deliver clinical proof of concept for this investigational treatment.

Our partner, Scout Bio, is offering compensation for referring DVMs who participate in successfully enrolling qualified patients and to the owners of the enrolled cats. Check our link for more information on full enrollment requirements.

HOW CAN YOU PARTICIPATE?

ELIGIBILITY

• Cats must be verified to be anemic (PCV ≤ 25) and in IRIS Stage II - IV CKD.
• Clients must commit to travel with their cat to the study site approximately every 2 weeks for a 90-126 day period. Clients must be willing and able to provide accurate assessments of their cat’s wellbeing and progress.

COSTS AND PROCEDURES COVERED:

There are no cost to owners for any study related exams, tests, or veterinary care.

All costs of examination and any needed diagnostics and laboratory evaluations are provided at no charge by the study site for the course of the study.

ADDITIONAL INCENTIVES:

Vet referrals and owners are eligible for compensation for their time. At completion, owners that comply with the study requirements will be compensated for their participation. Compensation ranges from $300-$500.

For referring DVMs: for each referral that is eligible for enrollment, Scout Bio will pay $200. in appreciation for your time and assistance.

Together, we can shape the future of CKD associated anemia.

Anemia creates issues like increased heart rate and breathing, weakness, lethargy, and significant inappetence. CKD associated anemia can dramatically decrease the quality of life for a client’s beloved geriatric cat. Participation in this trial will provide opportunity to try to help the individual pet, and may potentially help many future pet owners improve their beloved cats’ remaining time with them.

HOW DOES THERAPEUTIC TREATMENT WORK?

The therapy used in the study is designed to instruct the cat’s body to produce a feline protein erythropoietin (or “EPO”) by itself. After one or two injections, administered at the study site, there are no at home medications required.

** NO PLACEBO will be used in the study, so all cat owners will have peace of mind that their cat is getting the active treatment. Visit: www.scoutbio.co for more information about the study:

CONTACT INFORMATION: Allyson Berent, DVM, DACVIM, Study Investigator, Animal Medical Center (AMC)
Phone: 212.838.8100 | Email: jessica.mejia@amcny.org

The Elmer and Mamdouha Bobst Hospital | Anna-Maria and Stephen Kellen Institute for Postgraduate Education
Caspary Research Institute | The Cancer Institute
Emilia Saint-Amand Krimendahl Institute for Trauma Care | Ann and Charles Johnson One Health Institute
Usdan Institute for Animal Health Education